Also it may be that they are waiting for initial phase2 results on hsv to be positive before partnering because it will prove the professor has a viable vaccine platform. If this is proven could we see a deal with a partner for his entire vaccine platform incorporating many vaccines? The value for this would be far greater than HSV alone and give continued funding for the rest of his future vaccine development and the mind boggles when thinking on its dollar value. Just a thought
Nice finish, page-48
-
- There are more pages in this discussion • 26 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$12.22 |
Change
0.740(6.45%) |
Mkt cap ! $258.3M | |||
| Open | High | Low | Value | Volume |
| $11.50 | $12.25 | $11.49 | $395.2K | 33.29K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 100 | $11.70 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.22 | 127 | 1 |
View Market Depth
| Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
| AVR (ASX) Chart |